Global Oral Osmotic Laxative Market

Oral Osmotic Laxative Comprehensive Study by Drug (Sodium sulfate, Magnesium carbonate, Magnesium citrate, Lactitol, Mannitol), Form (Powder, Injectable, Syrup, Others), End Use (Over-the-Counter (OTC), Hospitals, Specialty Clinics, Prescription Based) Players and Region - Global Market Outlook to 2026

Oral Osmotic Laxative Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Oral Osmotic Laxative Market Study:
Abbott Laboratories (United States), Bayer AG (Germany), Procter and Gamble Company (United States), GlaxoSmithKline Consumer Healthcare (United Kingdom), Purdue Pharma (United States), Sucampo Pharmaceuticals (United States), Salix Pharmaceuticals (United States), Pharmos Corporation (United States), Lexicon Pharmaceuticals (United States) and Tioga Pharmaceuticals Inc. (United States)

In the last few years, Global market of Oral Osmotic Laxative developed rapidly. Major factors driving the market are Prevalence of Constipation Due to Rapid Changing Lifestyles .
Latest Industry Highlights:
On 9th March, 2020 - Food and Drug Administration (FDA) Approved Pizensy (lactitol; Sebela), an Oral Administration Osmotic Laxative used For the Treatment of Chronic Idiopathic Constipation (CIC) In Adult Patients. The Authorization was Based on The Results of Two Phase 3 Double-Blind Clinical Trials (Study 1, Study 2). and On 5th January, 2021 - Sebela Pharmaceuticals Announced Launch of SUTAB Tablets, As an Alternative to Liquid Colonoscopy Preparation, In US Market. SUTAB (Sodium Sulphate, Magnesium Sulphate, Potassium Chloride) Tablets Are Oral Osmotic Laxative Used to Cleanse the Colon in Adults in Preparation for A Colonoscopy..

Some of the other players that are also part of study are Alimentary Health Limited (Ireland), Perrigo Company plc (Ireland), Sebela Pharmaceuticals Inc. (United States) and Boehringer Ingelheim Pharmaceuticals (Germany). The Global Oral Osmotic Laxative market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Oral Osmotic Laxative market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Oral Osmotic Laxative market.
Identification of total players or companies operating in the global market which is further concentrated to a fewer or most impacting players which is considered under the report’s scope. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Oral Osmotic Laxative Manufactures, New Entrants and Investors, API Providers, Oral Osmotic Laxative Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Drug
  • Sodium sulfate
  • Magnesium carbonate
  • Magnesium citrate
  • Lactitol
  • Mannitol

By Form
  • Powder
  • Injectable
  • Syrup
  • Others

By End Use
  • Over-the-Counter (OTC)
  • Hospitals
  • Specialty Clinics
  • Prescription Based

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Constipation Due to Rapid Changing Lifestyles
      • 3.2.2. Increasing Junk Food Consumption
      • 3.2.3. Preference for Oral Laxatives over Injectables
    • 3.3. Market Challenges
      • 3.3.1. Regulatory Approval
      • 3.3.2. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Food Blogging/Vlogging trend Among Millennials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oral Osmotic Laxative, by Drug, Form, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Oral Osmotic Laxative (Value)
      • 5.2.1. Global Oral Osmotic Laxative by: Drug (Value)
        • 5.2.1.1. Sodium sulfate
        • 5.2.1.2. Magnesium carbonate
        • 5.2.1.3. Magnesium citrate
        • 5.2.1.4. Lactitol
        • 5.2.1.5. Mannitol
      • 5.2.2. Global Oral Osmotic Laxative by: Form (Value)
        • 5.2.2.1. Powder
        • 5.2.2.2. Injectable
        • 5.2.2.3. Syrup
        • 5.2.2.4. Others
      • 5.2.3. Global Oral Osmotic Laxative by: End Use (Value)
        • 5.2.3.1. Over-the-Counter (OTC)
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Specialty Clinics
        • 5.2.3.4. Prescription Based
      • 5.2.4. Global Oral Osmotic Laxative Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Oral Osmotic Laxative: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Procter and Gamble Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline Consumer Healthcare (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Purdue Pharma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sucampo Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Salix Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pharmos Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lexicon Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tioga Pharmaceuticals Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oral Osmotic Laxative Sale, by Drug, Form, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Oral Osmotic Laxative (Value)
      • 7.2.1. Global Oral Osmotic Laxative by: Drug (Value)
        • 7.2.1.1. Sodium sulfate
        • 7.2.1.2. Magnesium carbonate
        • 7.2.1.3. Magnesium citrate
        • 7.2.1.4. Lactitol
        • 7.2.1.5. Mannitol
      • 7.2.2. Global Oral Osmotic Laxative by: Form (Value)
        • 7.2.2.1. Powder
        • 7.2.2.2. Injectable
        • 7.2.2.3. Syrup
        • 7.2.2.4. Others
      • 7.2.3. Global Oral Osmotic Laxative by: End Use (Value)
        • 7.2.3.1. Over-the-Counter (OTC)
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Specialty Clinics
        • 7.2.3.4. Prescription Based
      • 7.2.4. Global Oral Osmotic Laxative Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oral Osmotic Laxative: by Drug(USD Million)
  • Table 2. Oral Osmotic Laxative Sodium sulfate , by Region USD Million (2015-2020)
  • Table 3. Oral Osmotic Laxative Magnesium carbonate , by Region USD Million (2015-2020)
  • Table 4. Oral Osmotic Laxative Magnesium citrate , by Region USD Million (2015-2020)
  • Table 5. Oral Osmotic Laxative Lactitol , by Region USD Million (2015-2020)
  • Table 6. Oral Osmotic Laxative Mannitol , by Region USD Million (2015-2020)
  • Table 7. Oral Osmotic Laxative: by Form(USD Million)
  • Table 8. Oral Osmotic Laxative Powder , by Region USD Million (2015-2020)
  • Table 9. Oral Osmotic Laxative Injectable , by Region USD Million (2015-2020)
  • Table 10. Oral Osmotic Laxative Syrup , by Region USD Million (2015-2020)
  • Table 11. Oral Osmotic Laxative Others , by Region USD Million (2015-2020)
  • Table 12. Oral Osmotic Laxative: by End Use(USD Million)
  • Table 13. Oral Osmotic Laxative Over-the-Counter (OTC) , by Region USD Million (2015-2020)
  • Table 14. Oral Osmotic Laxative Hospitals , by Region USD Million (2015-2020)
  • Table 15. Oral Osmotic Laxative Specialty Clinics , by Region USD Million (2015-2020)
  • Table 16. Oral Osmotic Laxative Prescription Based , by Region USD Million (2015-2020)
  • Table 17. South America Oral Osmotic Laxative, by Country USD Million (2015-2020)
  • Table 18. South America Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 19. South America Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 20. South America Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 21. Brazil Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 22. Brazil Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 23. Brazil Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 24. Argentina Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 25. Argentina Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 26. Argentina Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 27. Rest of South America Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 28. Rest of South America Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 29. Rest of South America Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 30. Asia Pacific Oral Osmotic Laxative, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 32. Asia Pacific Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 33. Asia Pacific Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 34. China Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 35. China Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 36. China Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 37. Japan Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 38. Japan Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 39. Japan Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 40. India Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 41. India Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 42. India Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 43. South Korea Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 44. South Korea Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 45. South Korea Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 46. Taiwan Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 47. Taiwan Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 48. Taiwan Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 49. Australia Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 50. Australia Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 51. Australia Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 55. Europe Oral Osmotic Laxative, by Country USD Million (2015-2020)
  • Table 56. Europe Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 57. Europe Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 58. Europe Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 59. Germany Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 60. Germany Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 61. Germany Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 62. France Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 63. France Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 64. France Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 65. Italy Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 66. Italy Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 67. Italy Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 68. United Kingdom Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 69. United Kingdom Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 70. United Kingdom Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 71. Netherlands Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 72. Netherlands Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 73. Netherlands Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 74. Rest of Europe Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 75. Rest of Europe Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 76. Rest of Europe Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 77. MEA Oral Osmotic Laxative, by Country USD Million (2015-2020)
  • Table 78. MEA Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 79. MEA Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 80. MEA Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 81. Middle East Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 82. Middle East Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 83. Middle East Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 84. Africa Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 85. Africa Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 86. Africa Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 87. North America Oral Osmotic Laxative, by Country USD Million (2015-2020)
  • Table 88. North America Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 89. North America Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 90. North America Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 91. United States Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 92. United States Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 93. United States Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 94. Canada Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 95. Canada Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 96. Canada Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 97. Mexico Oral Osmotic Laxative, by Drug USD Million (2015-2020)
  • Table 98. Mexico Oral Osmotic Laxative, by Form USD Million (2015-2020)
  • Table 99. Mexico Oral Osmotic Laxative, by End Use USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Oral Osmotic Laxative: by Drug(USD Million)
  • Table 111. Oral Osmotic Laxative Sodium sulfate , by Region USD Million (2021-2026)
  • Table 112. Oral Osmotic Laxative Magnesium carbonate , by Region USD Million (2021-2026)
  • Table 113. Oral Osmotic Laxative Magnesium citrate , by Region USD Million (2021-2026)
  • Table 114. Oral Osmotic Laxative Lactitol , by Region USD Million (2021-2026)
  • Table 115. Oral Osmotic Laxative Mannitol , by Region USD Million (2021-2026)
  • Table 116. Oral Osmotic Laxative: by Form(USD Million)
  • Table 117. Oral Osmotic Laxative Powder , by Region USD Million (2021-2026)
  • Table 118. Oral Osmotic Laxative Injectable , by Region USD Million (2021-2026)
  • Table 119. Oral Osmotic Laxative Syrup , by Region USD Million (2021-2026)
  • Table 120. Oral Osmotic Laxative Others , by Region USD Million (2021-2026)
  • Table 121. Oral Osmotic Laxative: by End Use(USD Million)
  • Table 122. Oral Osmotic Laxative Over-the-Counter (OTC) , by Region USD Million (2021-2026)
  • Table 123. Oral Osmotic Laxative Hospitals , by Region USD Million (2021-2026)
  • Table 124. Oral Osmotic Laxative Specialty Clinics , by Region USD Million (2021-2026)
  • Table 125. Oral Osmotic Laxative Prescription Based , by Region USD Million (2021-2026)
  • Table 126. South America Oral Osmotic Laxative, by Country USD Million (2021-2026)
  • Table 127. South America Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 128. South America Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 129. South America Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 130. Brazil Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 131. Brazil Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 132. Brazil Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 133. Argentina Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 134. Argentina Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 135. Argentina Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 136. Rest of South America Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 137. Rest of South America Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 138. Rest of South America Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 139. Asia Pacific Oral Osmotic Laxative, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 141. Asia Pacific Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 142. Asia Pacific Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 143. China Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 144. China Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 145. China Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 146. Japan Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 147. Japan Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 148. Japan Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 149. India Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 150. India Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 151. India Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 152. South Korea Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 153. South Korea Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 154. South Korea Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 155. Taiwan Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 156. Taiwan Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 157. Taiwan Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 158. Australia Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 159. Australia Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 160. Australia Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 164. Europe Oral Osmotic Laxative, by Country USD Million (2021-2026)
  • Table 165. Europe Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 166. Europe Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 167. Europe Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 168. Germany Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 169. Germany Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 170. Germany Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 171. France Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 172. France Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 173. France Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 174. Italy Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 175. Italy Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 176. Italy Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 177. United Kingdom Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 178. United Kingdom Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 179. United Kingdom Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 180. Netherlands Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 181. Netherlands Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 182. Netherlands Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 183. Rest of Europe Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 184. Rest of Europe Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 185. Rest of Europe Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 186. MEA Oral Osmotic Laxative, by Country USD Million (2021-2026)
  • Table 187. MEA Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 188. MEA Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 189. MEA Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 190. Middle East Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 191. Middle East Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 192. Middle East Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 193. Africa Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 194. Africa Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 195. Africa Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 196. North America Oral Osmotic Laxative, by Country USD Million (2021-2026)
  • Table 197. North America Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 198. North America Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 199. North America Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 200. United States Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 201. United States Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 202. United States Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 203. Canada Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 204. Canada Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 205. Canada Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 206. Mexico Oral Osmotic Laxative, by Drug USD Million (2021-2026)
  • Table 207. Mexico Oral Osmotic Laxative, by Form USD Million (2021-2026)
  • Table 208. Mexico Oral Osmotic Laxative, by End Use USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oral Osmotic Laxative: by Drug USD Million (2015-2020)
  • Figure 5. Global Oral Osmotic Laxative: by Form USD Million (2015-2020)
  • Figure 6. Global Oral Osmotic Laxative: by End Use USD Million (2015-2020)
  • Figure 7. South America Oral Osmotic Laxative Share (%), by Country
  • Figure 8. Asia Pacific Oral Osmotic Laxative Share (%), by Country
  • Figure 9. Europe Oral Osmotic Laxative Share (%), by Country
  • Figure 10. MEA Oral Osmotic Laxative Share (%), by Country
  • Figure 11. North America Oral Osmotic Laxative Share (%), by Country
  • Figure 12. Global Oral Osmotic Laxative share by Players 2020 (%)
  • Figure 13. Global Oral Osmotic Laxative share by Players (Top 3) 2020(%)
  • Figure 14. Global Oral Osmotic Laxative share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 20. Procter and Gamble Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Procter and Gamble Company (United States) Revenue: by Geography 2020
  • Figure 22. GlaxoSmithKline Consumer Healthcare (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Consumer Healthcare (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Purdue Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 25. Purdue Pharma (United States) Revenue: by Geography 2020
  • Figure 26. Sucampo Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Sucampo Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 28. Salix Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Salix Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 30. Pharmos Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pharmos Corporation (United States) Revenue: by Geography 2020
  • Figure 32. Lexicon Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Lexicon Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 34. Tioga Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Tioga Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Global Oral Osmotic Laxative: by Drug USD Million (2021-2026)
  • Figure 37. Global Oral Osmotic Laxative: by Form USD Million (2021-2026)
  • Figure 38. Global Oral Osmotic Laxative: by End Use USD Million (2021-2026)
  • Figure 39. South America Oral Osmotic Laxative Share (%), by Country
  • Figure 40. Asia Pacific Oral Osmotic Laxative Share (%), by Country
  • Figure 41. Europe Oral Osmotic Laxative Share (%), by Country
  • Figure 42. MEA Oral Osmotic Laxative Share (%), by Country
  • Figure 43. North America Oral Osmotic Laxative Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Procter and Gamble Company (United States)
  • GlaxoSmithKline Consumer Healthcare (United Kingdom)
  • Purdue Pharma (United States)
  • Sucampo Pharmaceuticals (United States)
  • Salix Pharmaceuticals (United States)
  • Pharmos Corporation (United States)
  • Lexicon Pharmaceuticals (United States)
  • Tioga Pharmaceuticals Inc. (United States)
Additional players considered in the study are as follows:
Alimentary Health Limited (Ireland) , Perrigo Company plc (Ireland) , Sebela Pharmaceuticals Inc. (United States) , Boehringer Ingelheim Pharmaceuticals (Germany)
Select User Access Type

Key Highlights of Report


Apr 2021 228 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oral Osmotic Laxative Market Quantitative research analysis
Global Oral Osmotic Laxative Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Food Blogging/Vlogging trend Among Millennials" is seen as one of major influencing trends for Oral Osmotic Laxative Market during projected period 2020-2026.
The Concentration Rate of Global Oral Osmotic Laxative market is highlighted using HHI Index.
United States Players will contribute the maximum growth of Global Oral Osmotic Laxative market throughout the predicted period.

Know More About Global Oral Osmotic Laxative Market Report?

Have a Query? Click Here

Other Related Reports

Urokinase Lyophilized Powder Comprehensive Study by Type (Less than 10000IU, 10000-100000IU, 100000-1000000IU, More than 1000000IU), Application (Eye Care, Cholesterol Embolization, Allergy Resistanc...
$ 3650
Gadopentetate Dimeglumine Comprehensive Study by End-User (Hospitals, Clinics), Dosage (10ml: 4.69g, 12ml: 5.63g, 15ml: 7.04g, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Signal Transduction Inhibitors Comprehensive Study by Type (Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Pazopanib, Sorafenib, Sunitinib), Application (Lung Cancer, Prostate Cance...
$ 3750
Pediatric Growth Hormones Comprehensive Study by Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Indication (Growth Hormone Deficiency, Turner Syndrome, Renal Insufficiency,...
$ 3650
Bovine Ephemeral Fever Vaccines Comprehensive Study by Application (Cattle, Buffaloes), Vaccine Type (Live Vaccine, Killed Vaccine), End User (Medical Device Companies, Pharmaceutical industries, An...
$ 3650
Dental Resin Composites Comprehensive Study by Type (Bulk fill composite, Universal composite, Flowable composite, Others), Application (Dental fillings, Dental crowns, Dental bridges, Others), Compo...
$ 3750